Neutralisation of CXCR4 with monoclonal antibodies in non-Hodgkin's lymphoma models has been proven to be effective in preventing pseudopodial formation and trans-endothelial migration in vitro and to protect against tumour challenge in vivo, reducing existing tumour growth while preventing tumour extravasation (Bertolini et al, 2002). The gene discussed is CXCR4; the disease is neoplasm.